Kazuhito Kawata

64PUBLICATIONS
164CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples life courseApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (64)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 17, 2026
Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow-Up.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|Jun 26, 2026
Metabolomics Approach Identifies Predictive Serum Markers for Hepatocellular Carcinogenesis Following Hepatitis C Virus Elimination.

|Jun 25, 2026
The Impact of Antithrombotic Therapy on Bleeding Complications in Percutaneous Liver Biopsy: Are the Withdrawal Criteria of Antithrombotic Agents in Japan Gastroenterological Endoscopy Society Guidelines for Gastroenterological Endoscopy Useful?

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Pageof 11

Frequent Collaborators

47 joint publications

Hidenori Toyoda

41 joint publications

Asahiro Morishita

39 joint publications

Atsushi Hiraoka

39 joint publications

Toshifumi Tada